GlassScriptPhysician profile
Spencer Allen Larkin
NPI 1235514282
$4,649.04
in general payments reported to CMS, 2019-2025
28 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $563 · 2021: $962 · 2022: $1,053 · 2023: $239 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.15 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,141.60 | 2019-2020 | |
| Boston Scientific Corporation | $738.29 | 2019-2025 | Ams 700, Spaceoar Vue System - 10ml |
| Axonics, INC. | $528.36 | 2020-2023 | Axonics |
| Astellas Pharma US INC | $471.53 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.68 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $178.56 | 2020-2022 | |
| Teleflex LLC | $154.67 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $140.59 | 2020-2021 | |
| Neotract INC. | $139.73 | 2019-2020 | |
| Antares Pharma, INC. | $137.09 | 2020-2022 | |
| Procept Biorobotics Corporation | $135.94 | 2020 | |
| Myriad Genetic Laboratories, INC. | $131.09 | 2021-2022 | |
| Urogen Pharma, INC. | $124.55 | 2022 | |
| Medtronic USA, INC. | $59.02 | 2019-2020 | |
| Amgen INC. | $48.58 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.53 | 2021-2022 | |
| Blue Earth Diagnostics | $42.95 | 2022 | |
| Janssen Biotech, INC. | $37.42 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Urovant Sciences INC | $24.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $22.00 | 2023 | Orgovyx |
| Myovant Sciences INC. | $21.03 | 2022 | |
| Smith+Nephew, INC. | $18.85 | 2022 | |
| Ethicon US, LLC | $18.73 | 2025 | Surgicel Nu-Knit |
| Abbvie INC. | $18.52 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $17.48 | 2020 | |
| Baudax Bio INC. | $13.00 | 2021 | |
| Allergan, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.